University of Tasmania
Browse

File(s) under permanent embargo

Pharmacoeconomic evidence of bosentan for pulmonary arterial hypertension

journal contribution
posted on 2023-05-17, 12:02 authored by Strange, G, Keogh, A, Dalton, B, Gabbay, E
In this article, we review randomized controlled trials, open-label trials and pharmacoeconomic models of bosentan for the management of patients with pulmonary arterial hypertension. Bosentan consistently improves WHO functional class and quality of life, slows clinical worsening and is associated with improved survival compared with historical treatment. Although headto- head trials are scarce, data directly comparing bosentan with sildenafil indicate no clinically significant differences between treatments as measured by the 6-min walk distance alone. Compared with historical care, bosentan treatment, over a 15–30-year period, increases the number of quality-adjusted life years (3.49 years). Economic modeling suggests that the cost–effectiveness of bosentan is similar to that of ambrisentan (US$43,725–57,778 per qualityadjusted life year), not as cost effective as sildenafil (at 20 mg three-times daily) and more cost effective than iloprost. More randomized controlled trials of longer duration are required to confirm the results from these economic models.

History

Publication title

Expert Review of Pharmacoeconomics & Outcomes Research

Volume

11

Pagination

253-263

ISSN

1473-7167

Department/School

School of Health Sciences

Publisher

Expert Reviews Ltd.

Place of publication

UK

Rights statement

Copyright 2011 Expert Reviews Ltd.

Repository Status

  • Restricted

Socio-economic Objectives

Evaluation of health outcomes